Novartis India
NSE: NOVARTIND · Pharmaceuticals
Snapshot
Unlock Novartis India's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Novartis India Limited is a healthcare company that markets a diverse portfolio of pharmaceutical and generic products. Its therapeutic focus spans bone and pain management, gynecology, neurosciences, and transplantation immunology.
Business Model
The company generates revenue through the commercialisation of established pharmaceutical brands and generic products within the Indian market. It operates as a subsidiary of the global pharmaceutical giant Novartis AG, leveraging its parent's established brand equity.
- Incorporation Year:1947
Growth Outlook
Growth is primarily driven by the sustained demand for its core therapeutic brands such as Voveran, Tegrital, and Exelon. The company continues to focus on its established portfolio in the Indian healthcare sector.
Key Risks
- Regulatory Pricing Pressure. The company faces significant risks from government-mandated price controls on essential medicines in India, which can compress profit margins.
- Generic Competition. The pharmaceutical sector in India is highly competitive, with numerous local manufacturers offering low-cost generic alternatives to established brands.
- Parent Company Dependency. As a subsidiary of Novartis AG, the company's strategic direction and product pipeline are heavily influenced by the global parent's corporate priorities.
- Supply Chain and Quality Compliance. Strict adherence to manufacturing standards and supply chain integrity is essential to avoid regulatory sanctions and reputational damage.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Novartis India and 5,000+ companies — free.
Key Metrics
REVENUE
₹354 Cr
TTM · standalone
NET PROFIT
₹93 Cr
TTM · standalone
EPS
₹37.75
TTM · standalone
RETURN ON EQUITY
11.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
16.1%
TTM · standalone
P/E
42.3x
Q4 FY26 · standalone
EV/EBITDA
29.5x
Q4 FY26 · standalone
EBITDA MARGIN
37.5%
TTM · standalone
NET PROFIT MARGIN
27.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Novartis IndiaNOVARTIND | 2,266 | 42.28 | 29.45 | -0.5% | 37.5% | 11.7% | 16.1% | +51.3% |
Dishman Carbogen Amcis LimitedDCAL | 2,294 | 31.26 | 8.09 | 8.1% | 21.2% | 1.6% | 3.3% | -26.3% |
IOL ChemicalsIOLCP | 2,287 | 34.98 | 16.82 | 11.5% | 12.5% | 8.0% | 11.0% | +75.6% |
Bliss GVS PharmaBLISSGVS | 2,193 | 41.29 | 22.41 | 14.5% | 25.6% | 12.4% | 17.4% | +219.3% |
Unichem Laboratories LimitedUNICHEMLAB | 2,111 | 16.84 | 18.17 | 8.5% | 11.1% | 10.0% | 12.2% | -6.3% |
Panacea BiotecPANACEABIO | 2,027 | -640.85 | 279.46 | 14.4% | 1.9% | -0.9% | -0.1% | +30.3% |
As of Q4 FY26
Financials
Novartis India
NSE: NOVARTIND · Pharmaceuticals
Snapshot
Unlock Novartis India's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Novartis India Limited is a healthcare company that markets a diverse portfolio of pharmaceutical and generic products. Its therapeutic focus spans bone and pain management, gynecology, neurosciences, and transplantation immunology.
Business Model
The company generates revenue through the commercialisation of established pharmaceutical brands and generic products within the Indian market. It operates as a subsidiary of the global pharmaceutical giant Novartis AG, leveraging its parent's established brand equity.
- Incorporation Year:1947
Growth Outlook
Growth is primarily driven by the sustained demand for its core therapeutic brands such as Voveran, Tegrital, and Exelon. The company continues to focus on its established portfolio in the Indian healthcare sector.
Key Risks
- Regulatory Pricing Pressure. The company faces significant risks from government-mandated price controls on essential medicines in India, which can compress profit margins.
- Generic Competition. The pharmaceutical sector in India is highly competitive, with numerous local manufacturers offering low-cost generic alternatives to established brands.
- Parent Company Dependency. As a subsidiary of Novartis AG, the company's strategic direction and product pipeline are heavily influenced by the global parent's corporate priorities.
- Supply Chain and Quality Compliance. Strict adherence to manufacturing standards and supply chain integrity is essential to avoid regulatory sanctions and reputational damage.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Novartis India and 5,000+ companies — free.
Key Metrics
REVENUE
₹354 Cr
TTM · standalone
NET PROFIT
₹93 Cr
TTM · standalone
EPS
₹37.75
TTM · standalone
RETURN ON EQUITY
11.7%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
16.1%
TTM · standalone
P/E
42.3x
Q4 FY26 · standalone
EV/EBITDA
29.5x
Q4 FY26 · standalone
EBITDA MARGIN
37.5%
TTM · standalone
NET PROFIT MARGIN
27.9%
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26